key: cord-0705761-vq1icdc6
authors: Dey, Raghunath; Nayak, Sourav; Das, Parthasarathi; Yadav, Somnath
title: Short Synthesis of Molnupiravir (EIDD-2801) via a Thionated Uridine Intermediate
date: 2021-10-11
journal: ACS Omega
DOI: 10.1021/acsomega.1c04550
sha: 13518118c7b1db59669890b07f057210f93e601b
doc_id: 705761
cord_uid: vq1icdc6

[Image: see text] Molnupiravir (MK-4482, EIDD-2801) is an experimental drug that has been demonstrated to be effective for the treatment of COVID-19 in human clinical trials. Herein, we report a concise synthesis of the drug via a novel thionated derivative that relies on one-pot methodologies, thus decreasing the number of purification steps required. This route provides the drug in an overall 62% yield and >99% purity and uses cheap and readily available bulk chemicals, thereby providing an affordable synthesis of the drug for cheaper and wider global accessibility.

Molnupiravir (MK-4482, EIDD-2801) is an anti-influenza drug initially developed by Emory University. 1 Subsequently, with the advent of COVID-19, it was repurposed for the treatment of the disease with a fair amount of success in animal models. 2 Currently, the drug is being evaluated in human trials for COVID-19. 3 The mechanism of action of the drug has been demonstrated to be through molnupiravir-induced RNA mutagenesis by the RNA-dependent RNA polymerase (RdRp) of the coronavirus SARS- Compared to the other experimental drugs that have been approved for emergency use in the treatment of COVID-19, molnupiravir offers the advantage of being able to be administered orally. Due to the importance of the drug as potential treatment for the pandemic of COVID-19 through oral delivery outside of hospitalization, there is a huge interest in developing efficient and cost-effective synthesis for its bulk production.

Structurally, molnupiravir is N-hydroxycytidine. To date, there are a few reports of its synthesis with different levels of complexities associated with it (Scheme 1). The first synthetic route reported by Emory University involved five steps from uridine with unclear yields and the costly reagent 1,2,4triazole. 5 Kappe and co-workers improved upon the previous route by reordering the sequence of steps that allowed the synthesis to be carried out in four steps. However, the route included the costly 1,2,4-triazole. 6 Subsequently, Snead and coworkers addressed the issue of the number of steps by reporting a two-step synthesis from cytidine that relied on the Novozyme-435-catalyzed esterification of C5-OH using isobutyryl acetone oxime ester. 7 Subsequently, the same group reported an improvement of the process by optimizing the reaction conditions and decreasing the loading of the enzyme catalyst in the first step, while increasing the stoichiometry of the hydroxylamine sulfate in the second step. 8 This significantly increased the yield in both steps while avoiding chromatographic separations. Among other drawbacks of the process, one is the use of Novozyme-435, which is associated with several problems such as high cost, catalyst recycling, enzyme leaching leading to contamination of the product, mechanical fragility, and product purification. 9 Snead and co-workers subsequently reported another method that used cytidine and involved a higher number of (three) steps with an overall yield of 44% but avoided the use of the Novozyme-435 catalyst and the isobutyryl acetone oxime ester. 10 Fier and co-workers reported a three-step route that used much cheaper ribose as starting material. However, this route still involved the use of Novozyme-435 for the esterification reaction and a mixture of several other enzymes for the synthesis of the intermediate cytidine. 11 Another disadvantage of the method is that it used the costly HMDS as the solvent along with 0.5 equiv of imidazole for the hydroxamination reaction. Thus, it can be concluded that with the associated disadvantages of the previously reported routes to Molnupiravir, more efficient and cost-effective routes that use commonly available and cheaper commodity chemicals need to be designed for making it affordable to the financially weaker communities of the world affected by the COVID-19 pandemic. Toward this end, very recently, Snead Scheme 1. Previous and Present Routes to Molnupiravir Scheme 2. Our Retrosynthetic Strategy for the Synthesis of Molnupiravir and co-workers reported a two-step synthesis of Molnupiravir from cytidine involving direct oxime formation from cytidine followed by esterification of the sugar C5′-OH using Novozyme. 12 Herein, we report a two-step, gram-scale synthesis of Molnupiravir involving a novel thionated intermediate and one-pot operations affording the final product in a 62% overall yield and >99% purity. 13 Further, the route uses only cheap bulk chemicals that are easily available.

The retrosynthetic strategy for our synthesis of molnupiravir is outlined in Scheme 2. The strategy relied on the C4 thionated compound 2 as the key intermediate that could be easily converted to the N 4 -hydroxyl group. 14 Compound 2, in turn, could be easily synthesized selectively by the regioselective thionation of the C4 carbonyl of a suitably protected uridine derivative using Lawesson's reagent.

We started our work on the synthesis of the key intermediate 2 by following the previously reported procedure for acetonide protection and isobutyl ester formation. 5 During the optimization of the conditions for the one-pot sequential acetonide protection and esterification of uridine, we observed that acetonide protection could be carried out in less than 1 h using acetone and a catalytic amount of sulfuric acid. For the subsequent isobutyrylation of C5′-OH, it was found that neutralization of H 2 SO 4 , followed by replacement of acetone as the solvent by acetonitrile, led to greater consistency of product formation and decreased the reaction time to 1 h without compromising the yield (Scheme 3).

Next, the conditions for conversion of 5 to the thionated derivative 2 were explored using Lawesson's reagent in various solvents under reflux ( Table 1) . Optimization of the conditions led to the conclusion that the reaction was best carried out Scheme 3. Optimized Synthesis of Intermediate 5 with 0.5 equiv of Lawesson's reagent in refluxing toluene as solvent, affording the desired product 2 in 86% yield after 15 min. Next, we optimized the condition for transformation of the thionated compound 2 to N-hydroxy compound 6 ( Table 2) . Combinations of several hydroxylamine salts and solvents were explored for the reaction, which led to the conclusion that the reaction could be carried out best using aqueous hydroxylamine in MeOH as solvent affording the product 6 in 80% yield after 1 h of reaction.

Following the optimization of the conditions for the individual steps of the synthesis of intermediate 2, the sequential and streamlined synthesis of molnupiravir was carried out on a 5 gram scale (Scheme 4). Starting from uridine, the sequential acetonation of its C2′ and C3′ hydroxyls followed by C5′ esterification was carried out using the optimized conditions. Then, the crude product obtained was treated with Lawesson's reagent under the optimized conditions to afford the pure product 2 in 81% yield after chromatographic separation. Compound 2 was then treated with aqueous hydroxylamine in MeOH for 1 h to convert it to the oxime, after which methanol was removed under reduced pressure and formic acid was added to the residue in one pot as per the Emory University route 5 to afford pure molnupiravir in 62% yield and >99% purity after chromatographic separation.

In summary, we have developed a gram-scale synthesis of molnupiravir from commercially available uridine in two steps in an overall yield of 62% with greater than 99% purity. The individual steps in the reaction were implemented in shorter times that provide opportunities for cost-effective production on a large scale. The novel thionated intermediate used in the synthesis leads to the easy and high-yielding introduction of the N-hydroxy group through the use of a simple bulk chemical. Although the use of smelly Lawesson's reagent may be an issue in some instances, it can be overcome through careful handling of the reaction under controlled environments. However, the advantage of the present route is that it uses familiar laboratory techniques and common chemicals. Also, the present route is appealing because it requires considerably less time than all of the other previous routes.

Although a very precise head-to-head cost comparison of the present method vis-a-vis previous methods is not feasible at this moment, this aspect can be covered by implementing the process on a larger scale in the kilolab. However, we believe that aside from uridine, which costs more than cytidine used previously, all of the other reagents used here are substantially cheaper than the ones previously used. These factors together with the lesser overall processing time required for the present method make it a cost-effective method for the bulk synthesis of molnupiravir. While the use of column chromatography is inconvenient for large-scale production, this aspect could be addressed when the process moves to a larger scale. This would provide the opportunity for the affordable and fast delivery of the API for global access to the drug for treatment of COVID-19.

4.1. General Information. All reactions were carried out under an inert atmosphere with oven-dried glassware. All solvents and reagents were obtained from commercial sources and were purified following the standard procedure prior to use. The developed chromatogram was analyzed using a UV lamp (254 nm) or vanillin stain. Products were purified by flash chromatography on silica gel (mesh size 230−400). Unless otherwise specified, all of the 1 H NMR and 13 C NMR spectra were recorded in CDCl 3 or DMSO-D 6 . Chemical shifts of 1 H and 13 C NMR spectra are expressed in parts per million (ppm). All coupling constants are absolute values and are expressed in hertz. The description of the signals includes the following: s = singlet, d = doublet, dd = doublet of doublet, t = triplet, dt = doublet of triplet, q = quartet, br = broad, and m = multiplet.

4.2. Synthesis of ((3aR,4R,6R,6aR)-6-(2,4-dioxo-3,4d i h y d r o p y r i m i d i n -1 ( 2 H ) -y l ) -2 , 2dimethyltetrahydrofuro[3,4-d] [1, 3] dioxol-4-yl)methyl Isobutyrate (5) . To a round-bottom flask charged with uridine (200 mg, 0.82 mmol) and acetone (4 mL), sulfuric acid (9 μL, 0.16 mmol) was added, and the mixture was stirred at ambient temperature for 45 min. After completion of the reaction (when a clear reddish-brown solution was obtained), the acid was neutralized by adding triethylamine (0.5 mL), after which the volatile components were removed under a reduced pressure to furnish a colorless syrup. The syrup was then redissolved in acetonitrile (5 mL) and triethylamine (230 μL, 1.4 mmol), and isobutyric anhydride (0.27 mL, 1.4 mmol) and 4-dimethylaminopyridine (20 mg, 0.14 mmol) were added sequentially to the reaction mixture. The mixture was stirred at ambient temperature for 60 min until the starting material disappeared (as monitored using thin-layer chromatography (TLC)). Then, the solvent was evaporated under reduced pressure, and the residue was dissolved in ethyl acetate (25 mL) and washed with water (3 × 10 mL). The organic layer was separated and dried with anhydrous sodium sulfate, after which it was concentrated under reduced pressure. The residue was then subjected to column chromatography on silica gel (230−400 mesh) using ethyl acetate−hexane (4.5:5.5) as an eluent to afford the desired product 5 (228 mg, 92%) as a colorless sticky liquid. 1 176.7, 163.5, 150.1, 142.2, 114.7,  102.6, 94.9, 85.5, 84.8, 81.2, 64.1, 34.0, 27.3, 25.4, 19.1, 19 4.3. Optimization of the Procedure for the Synthesis of 2,2-Dimethyl-6-(2-oxo-4-thioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuro [3,4-d] [1, 3] dioxol-4-yl)methyl Isobutyrate (2) . Compound 5 (200 mg, 0.56 mmol) was dissolved in an appropriate solvent (4 mL), and Lawesson's reagent (as per Table 1 ) was added to it. The resulting mixture was refluxed for appropriate time as indicated in Table 1 . After complete consumption of the starting material (as monitored using TLC), the reaction mixture was concentrated and loaded onto a silica gel (230−400 mesh) column. The desired compound was eluted using a 2:8 mixture of ethyl acetate and hexanes as the eluent to furnish product 2 in yields indicated in Table 1 (2) . To a solution of uridine (5 g, 20.5 mmol) in acetone (80 mL) taken in a round-bottom flask, sulfuric acid (0.6 mL, 10.67 mmol) was added to the mixture, following which the mixture was stirred for 1 h. After completion of the reaction (when a clear reddish-brown solution was obtained), the acid was neutralized using solid sodium bicarbonate, and the solid precipitated was filtered. The filtrate was concentrated under reduced pressure to obtain an oily liquid. The oily liquid obtained above was redissolved in ACN (80 mL), and then 4dimethylaminopyridine (DMAP, 500 mg, 4.1 mmol), triethylamine (5.7 mL, 41 mmol), and isobutyric anhydride (6.8 mL, 41 mmol) were successively added to the solution. The reaction mixture was stirred at ambient temperature for 1 h, after which the mixture was diluted by adding 500 mL of ethyl acetate (EA) and washed successively with 150 mL of water three times. The organic layer was then removed, dried over anhydrous sodium sulfate, and concentrated to afford a sticky liquid.

The crude product obtained above was dissolved in toluene (100 mL), and Lawesson's reagent (8.2 g, 20.5 mmol) was added to it. The resulting mixture was refluxed for 15 min, after which it was cooled, concentrated under reduced pressure, and then subjected to column chromatography over a column of silica gel. The column was eluted with a 2:8 mixture of ethyl acetate and hexane as the eluent, following which 2 (6.14 g (81% yield)) was obtained as a light-yellow solid. (1). To a solution of 2 (6.14 g. 16.58 mmol) in MeOH (50 mL) taken in a round-bottom flask, 50% aqueous solution of hydroxylamine (3.3 mL, 50 mmol) was added, and then the reaction mixture was stirred at ambient temperature for 1 h. After completion of the reaction (monitored using TLC), MeOH was removed under reduced pressure and formic acid (50 mL) was added to the residue. The mixture was stirred at ambient temperature overnight. Then, 80 mL of MeOH was added to the mixture, following which the solution was concentrated under reduced pressure and subjected to column chromatography over a column of silica gel. Elution of the column with MeOH-DCM (1:19) afforded 1 (4.15 g, 76% yield) as a white solid. Mp: 158−160°C, 1 The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.1c04550.

Copies of 1 H, 13 

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

2021, 28, 740−746. (b) Menéndez-Arias, L. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2

A High-Yielding Synthesis of EIDD-2801 from Uridine

A Concise Route to MK-4482 (EIDD-2801) from Cytidine

Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine

Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2

Evolving to an Ideal Synthesis of Molnupiravir

Toward a Practical, Two-Step Process for Molnupiravir: Direct Hydroxamination of Cytidine Followed by Selective Esterification

A Process for the Preparation of Molnupiravir (EIDD-2801)

N 4 -Hydroxycytosine Dioxolane Nucleosides and Their Activity Against Hepatitis B Virus